{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:14:12Z","timestamp":1783498452727,"version":"3.55.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00415-026-13933-8","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:11:25Z","timestamp":1781521885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarkers stewardship in parkinsonism: integrating alpha-synuclein seed amplification assays and neurofilament light chain into diagnostic pathways and patient communication"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6534-8819","authenticated-orcid":false,"given":"Vincent","family":"Leclercq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"5","key":"13933_CR1","doi-asserted-by":"publisher","first-page":"S175","DOI":"10.1016\/j.jacr.2020.01.042","volume":"17","author":"HB Harvey","year":"2020","unstructured":"Harvey HB, Watson LC, Subramaniam RM et al (2020) ACR Appropriateness Criteria\u00ae movement disorders and neurodegenerative diseases. J Am Coll Radiol 17(5):S175\u2013S187","journal-title":"J Am Coll Radiol"},{"issue":"12","key":"13933_CR2","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3174\/ajnr.A8313","volume":"45","author":"G Keir","year":"2024","unstructured":"Keir G, Roytman M, Mashriqi F, Shahsavarani S, Franceschi AM (2024) Atypical Parkinsonian syndromes: structural, functional, and molecular imaging features. AJNR Am J Neuroradiol 45(12):1865\u20131877. https:\/\/doi.org\/10.3174\/ajnr.A8313","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"13933_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/jnc.14698","volume":"150","author":"L Walker","year":"2019","unstructured":"Walker L, Stefanis L, Attems J (2019) Clinical and neuropathological differences between Parkinson\u2019s disease, Parkinson\u2019s disease dementia and dementia with Lewy bodies \u2013 current issues and future directions. J Neurochem 150(5):467\u2013474. https:\/\/doi.org\/10.1111\/jnc.14698","journal-title":"J Neurochem"},{"key":"13933_CR4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041610","author":"DW Dickson","year":"2025","unstructured":"Dickson DW (2025) Neuropathology of Parkinson\u2019s disease and Parkinsonism. Cold Spring Harb Perspect Med. https:\/\/doi.org\/10.1101\/cshperspect.a041610","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"13933_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ncl.2024.12.006","volume":"43","author":"N Olfati","year":"2025","unstructured":"Olfati N, Akhoundi FH, Litvan I (2025) Atypical parkinsonian disorders. Neurol Clin 43(2):249\u2013277","journal-title":"Neurol Clin"},{"issue":"10291","key":"13933_CR6","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. Lancet 397(10291):2284\u20132303. https:\/\/doi.org\/10.1016\/S0140-6736(21)00218-X","journal-title":"Lancet"},{"issue":"5","key":"13933_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W (2021) Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol 20(5):385\u2013397. https:\/\/doi.org\/10.1016\/S1474-4422(21)00030-2","journal-title":"Lancet Neurol"},{"issue":"6","key":"13933_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/neup.12777","volume":"41","author":"Y Toyoshima","year":"2021","unstructured":"Toyoshima Y, Takahashi H, Katada S et al (2021) Parkinson\u2019s disease and parkinsonism: clinicopathological discrepancies on diagnosis in three patients. Neuropathology 41(6):450\u2013456. https:\/\/doi.org\/10.1111\/neup.12777","journal-title":"Neuropathology"},{"issue":"8","key":"13933_CR9","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1093\/brain\/awad105","volume":"146","author":"D Street","year":"2023","unstructured":"Street D, Jabbari E, Costantini A et al (2023) Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials. Brain 146(8):3232\u20133242. https:\/\/doi.org\/10.1093\/brain\/awad105","journal-title":"Brain"},{"issue":"8","key":"13933_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S1474-4422(25)00194-2","volume":"24","author":"J Agin-Liebes","year":"2025","unstructured":"Agin-Liebes J, Lodge A, Reddy H et al (2025) \u03b1-synuclein biomarker assays: bridging research and patient care. Lancet Neurol 24(8):681\u2013697. https:\/\/doi.org\/10.1016\/S1474-4422(25)00194-2","journal-title":"Lancet Neurol"},{"issue":"12","key":"13933_CR11","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1093\/brain\/awad265","volume":"146","author":"N Vijiaratnam","year":"2023","unstructured":"Vijiaratnam N, Foltynie T (2023) How should we be using biomarkers in trials of disease modification in Parkinson\u2019s disease? Brain 146(12):4845\u20134869. https:\/\/doi.org\/10.1093\/brain\/awad265","journal-title":"Brain"},{"issue":"2","key":"13933_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger GU, Adler CH, Berg D et al (2024) A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol 23(2):191\u2013204. https:\/\/doi.org\/10.1016\/S1474-4422(23)00404-0","journal-title":"Lancet Neurol"},{"issue":"10423","key":"13933_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH (2024) The pathogenesis of Parkinson\u2019s disease. The Lancet 403(10423):293\u2013304. https:\/\/doi.org\/10.1016\/S0140-6736(23)01478-2","journal-title":"The Lancet"},{"issue":"12","key":"13933_CR14","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/S1474-4422(24)00396-X","volume":"23","author":"F Krismer","year":"2024","unstructured":"Krismer F, Fanciulli A, Meissner WG, Coon EA, Wenning GK (2024) Multiple system atrophy: advances in pathophysiology, diagnosis, and treatment. Lancet Neurol 23(12):1252\u20131266. https:\/\/doi.org\/10.1016\/S1474-4422(24)00396-X","journal-title":"Lancet Neurol"},{"issue":"12","key":"13933_CR15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00415-025-13546-7","volume":"272","author":"S Li","year":"2025","unstructured":"Li S, Yang C, Wu J et al (2025) Cerebrospinal fluid biomarkers for diagnosis of Parkinson\u2019s disease: a systematic review and network meta-analysis. J Neurol 272(12):793. https:\/\/doi.org\/10.1007\/s00415-025-13546-7","journal-title":"J Neurol"},{"issue":"5","key":"13933_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant D-E et al (2023) Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol 22(5):407\u2013417. https:\/\/doi.org\/10.1016\/S1474-4422(23)00109-6","journal-title":"Lancet Neurol"},{"issue":"1","key":"13933_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/brain\/awad260","volume":"147","author":"A Chopra","year":"2024","unstructured":"Chopra A, Outeiro TF (2024) Aggregation and beyond: alpha-synuclein-based biomarkers in synucleinopathies. Brain 147(1):81\u201390. https:\/\/doi.org\/10.1093\/brain\/awad260","journal-title":"Brain"},{"issue":"4","key":"13933_CR18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/mds.29329","volume":"38","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio L, Weber S, Farris CM et al (2023) Accurate detection of \u03b1-Synuclein seeds in CSF from iRBD and Parkinson patients in the DeNoPa cohort. Mov Disord Offi J Mov Disord Soc 38(4):567","journal-title":"Mov Disord Offi J Mov Disord Soc"},{"issue":"7","key":"13933_CR19","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S1474-4422(25)00157-7","volume":"24","author":"CD Orr\u00fa","year":"2025","unstructured":"Orr\u00fa CD, Vaughan DP, Vijiaratnam N et al (2025) Diagnostic and prognostic value of \u03b1-synuclein seed amplification assay kinetic measures in Parkinson\u2019s disease: a longitudinal cohort study. Lancet Neurol 24(7):580\u2013590. https:\/\/doi.org\/10.1016\/S1474-4422(25)00157-7","journal-title":"Lancet Neurol"},{"issue":"3","key":"13933_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214648","volume":"106","author":"DG Coughlin","year":"2026","unstructured":"Coughlin DG, Adler CH, Barbosa W et al (2026) CSF \u03b1-Synuclein seed amplification assays and skin immunofluorescence: clinical applications, research opportunities, and knowledge gaps. Neurology 106(3):e214648. https:\/\/doi.org\/10.1212\/WNL.0000000000214648","journal-title":"Neurology"},{"issue":"5","key":"13933_CR21","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00702-025-03070-3","volume":"133","author":"A Perez-Soriano","year":"2026","unstructured":"Perez-Soriano A, Painous C, Fernandez M et al (2026) Neurofilament light chain as a diagnostic and prognostic biomarker in atypical parkinsonisms: current evidence, new data, challenges, and future directions. J Neural Transm (Vienna) 133(5):853\u2013864. https:\/\/doi.org\/10.1007\/s00702-025-03070-3","journal-title":"J Neural Transm (Vienna)"},{"issue":"6","key":"13933_CR22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","volume":"18","author":"L Parnetti","year":"2019","unstructured":"Parnetti L, Gaetani L, Eusebi P et al (2019) CSF and blood biomarkers for Parkinson\u2019s disease. Lancet Neurol 18(6):573\u2013586. https:\/\/doi.org\/10.1016\/S1474-4422(19)30024-9","journal-title":"Lancet Neurol"},{"issue":"4","key":"13933_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13051-x","volume":"272","author":"W Kou","year":"2025","unstructured":"Kou W, Li S, Yan R et al (2025) Cerebrospinal fluid and blood neurofilament light chain in Parkinson\u2019s disease and atypical parkinsonian syndromes: a systematic review and Bayesian network meta-analysis. J Neurol 272(4):311. https:\/\/doi.org\/10.1007\/s00415-025-13051-x","journal-title":"J Neurol"},{"issue":"5","key":"13933_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1212\/WNL.0000000000200878","volume":"99","author":"G Bellomo","year":"2022","unstructured":"Bellomo G, De Luca CMG, Paoletti FP et al (2022) \u03b1-Synuclein seed amplification assays for diagnosing synucleinopathies: the way forward. Neurology 99(5):195\u2013205. https:\/\/doi.org\/10.1212\/WNL.0000000000200878","journal-title":"Neurology"},{"issue":"6","key":"13933_CR25","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1007\/s11010-024-05190-y","volume":"480","author":"E Carrazana","year":"2025","unstructured":"Carrazana E, Montalb\u00e1n-Guti\u00e9rrez L, Chana-Cuevas P, Salvadores N (2025) Advancing Parkinson\u2019s diagnosis: seed amplification assay for \u03b1-synuclein detection in minimally invasive samples. Mol Cell Biochem 480(6):3297\u20133314. https:\/\/doi.org\/10.1007\/s11010-024-05190-y","journal-title":"Mol Cell Biochem"},{"key":"13933_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2024.105997","volume":"169","author":"C Salciccia","year":"2025","unstructured":"Salciccia C, Costanzo M, Ruocco G et al (2025) Proteopathic seed amplification assays in easily accessible specimens for human synucleinopathies, tauopathies, and prionopathies: a scoping review. Neurosci Biobehav Rev 169:105997. https:\/\/doi.org\/10.1016\/j.neubiorev.2024.105997","journal-title":"Neurosci Biobehav Rev"},{"key":"13933_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2025.120517","volume":"578","author":"S Udayakumar","year":"2026","unstructured":"Udayakumar S, Girigoswami A, Girigoswami K (2026) Liquid biopsy in neurodegenerative disease: a minimally invasive approach for early diagnosis. Clin Chim Acta 578:120517. https:\/\/doi.org\/10.1016\/j.cca.2025.120517","journal-title":"Clin Chim Acta"},{"issue":"2","key":"13933_CR28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K et al (2024) A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol 23(2):178\u2013190. https:\/\/doi.org\/10.1016\/S1474-4422(23)00405-2","journal-title":"Lancet Neurol"},{"key":"13933_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-025-03013-y","author":"NGD Reyes","year":"2025","unstructured":"Reyes NGD, Pajo AT, Saranza G, H\u00f6glinger GU, Lang AE (2025) Revisiting Parkinson\u2019s disease definition and classification: insights from two emerging biological frameworks. J Neural Transm. https:\/\/doi.org\/10.1007\/s00702-025-03013-y","journal-title":"J Neural Transm"},{"key":"13933_CR30","doi-asserted-by":"publisher","DOI":"10.1101\/2022.02.28.22271232","author":"MR Arnold","year":"2022","unstructured":"Arnold MR, Coughlin DG, Brumbach BH et al (2022) Cerebrospinal fluid and brain \u03b1-synuclein seed amplification in autopsy-confirmed Lewy body disease relates to the distribution of pathology. medRxiv. https:\/\/doi.org\/10.1101\/2022.02.28.22271232","journal-title":"medRxiv"},{"issue":"1","key":"13933_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-023-02663-0","volume":"147","author":"GM Bentivenga","year":"2024","unstructured":"Bentivenga GM, Mammana A, Baiardi S et al (2024) Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. Acta Neuropathol 147(1):18. https:\/\/doi.org\/10.1007\/s00401-023-02663-0","journal-title":"Acta Neuropathol"},{"key":"13933_CR32","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000214040","author":"D Esteller-Gauxax","year":"2025","unstructured":"Esteller-Gauxax D, P\u00e9rez Millan A, Sarto J et al (2025) \u03b1-synuclein seed amplifications assay in a cohort with cognitive impairment. Neurology. https:\/\/doi.org\/10.1212\/wnl.0000000000214040","journal-title":"Neurology"},{"issue":"4","key":"13933_CR33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214614","volume":"106","author":"R Kumar","year":"2026","unstructured":"Kumar R, Gravett S, Jelic V et al (2026) Diagnostic performance of the \u03b1-synuclein seed amplification assay for dementia with Lewy bodies: a comparison across 4 laboratories. Neurology 106(4):e214614. https:\/\/doi.org\/10.1212\/WNL.0000000000214614","journal-title":"Neurology"},{"issue":"12","key":"13933_CR34","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1474-4422(24)00395-8","volume":"23","author":"Y Ma","year":"2024","unstructured":"Ma Y, Farris CM, Weber S et al (2024) Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study. Lancet Neurol 23(12):1225\u20131237. https:\/\/doi.org\/10.1016\/S1474-4422(24)00395-8","journal-title":"Lancet Neurol"},{"key":"13933_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.parkreldis.2022.05.006","volume":"99","author":"Y Compta","year":"2022","unstructured":"Compta Y, Painous C, Soto M et al (2022) Combined CSF \u03b1-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: from bedside to bench, and back again. Parkinsonism Relat Disord 99:33\u201341. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.05.006","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"13933_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","volume":"140","author":"M Rossi","year":"2020","unstructured":"Rossi M, Candelise N, Baiardi S et al (2020) Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 140(1):49\u201362. https:\/\/doi.org\/10.1007\/s00401-020-02160-8","journal-title":"Acta Neuropathol"},{"issue":"7794","key":"13933_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz M, Mukherjee A, Pritzkow S et al (2020) Discriminating \u03b1-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature 578(7794):273\u2013277. https:\/\/doi.org\/10.1038\/s41586-020-1984-7","journal-title":"Nature"},{"issue":"6","key":"13933_CR38","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi A, Hatano T, Matsumoto G et al (2023) Propagative \u03b1-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med 29(6):1448\u20131455. https:\/\/doi.org\/10.1038\/s41591-023-02358-9","journal-title":"Nat Med"},{"issue":"3","key":"13933_CR39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ana.25824","volume":"88","author":"W Singer","year":"2020","unstructured":"Singer W, Schmeichel AM, Shahnawaz M et al (2020) Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from Lewy body synucleinopathies. Ann Neurol 88(3):503\u2013512. https:\/\/doi.org\/10.1002\/ana.25824","journal-title":"Ann Neurol"},{"key":"13933_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01705-x","author":"J Li","year":"2024","unstructured":"Li J, Duan S, Yang J et al (2024) Detection of skin \u03b1-synuclein using RT-QuIC as a diagnostic biomarker for Parkinson\u2019s disease in the Chinese population. Eur J Med Res. https:\/\/doi.org\/10.1186\/s40001-024-01705-x","journal-title":"Eur J Med Res"},{"key":"13933_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00738-7","author":"Y Kuang","year":"2024","unstructured":"Kuang Y, Mao H, Gan T et al (2024) A skin-specific \u03b1-Synuclein seeding amplification assay for diagnosing Parkinson\u2019s disease. npj Parkinsons Dis. https:\/\/doi.org\/10.1038\/s41531-024-00738-7","journal-title":"npj Parkinsons Dis"},{"key":"13933_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-025-02034-8","author":"R Bsoul","year":"2025","unstructured":"Bsoul R, McWilliam OH, Waldemar G et al (2025) Accurate detection of pathologic \u03b1-synuclein in CSF, skin, olfactory mucosa, and urine with a uniform seeding amplification assay. Acta Neuropathol Commun. https:\/\/doi.org\/10.1186\/s40478-025-02034-8","journal-title":"Acta Neuropathol Commun"},{"key":"13933_CR43","doi-asserted-by":"publisher","unstructured":"Diana Angelika O, Ivan M-V, Naomi P V, et al. A rapid, novel, ultra-sensitive RT-QuIC, for MSA\/PD using skin biopsy\/serum neurofilament light chain. In: Association of British Neurologists: Annual Meeting Abstracts 2023. BMJ Publishing Group Ltd, pp. A6.2-A6. https:\/\/doi.org\/10.1136\/jnnp-2023-abn.17","DOI":"10.1136\/jnnp-2023-abn.17"},{"key":"13933_CR44","doi-asserted-by":"publisher","unstructured":"Zhao Y, Luan M, Liu J, et al. Skin \u03b1-synuclein assays in diagnosing Parkinson\u2019s disease: a systematic review and meta-analysis. Journal of Neurology. https:\/\/doi.org\/10.1007\/s00415-025-12978-5","DOI":"10.1007\/s00415-025-12978-5"},{"issue":"5","key":"13933_CR45","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1212\/wnl.0000000000002919","volume":"87","author":"CH Gibbons","year":"2016","unstructured":"Gibbons CH, Garcia J, Wang N, Shih LC, Freeman R (2016) The diagnostic discrimination of cutaneous \u03b1-synuclein deposition in Parkinson disease. Neurology 87(5):505\u2013512. https:\/\/doi.org\/10.1212\/wnl.0000000000002919","journal-title":"Neurology"},{"key":"13933_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-021-00242-2","author":"A Kuzkina","year":"2021","unstructured":"Kuzkina A, Bargar C, Schmitt D et al (2021) Diagnostic value of skin RT-QuIC in Parkinson\u2019s disease: a two-laboratory study. npj Parkinsons Dis. https:\/\/doi.org\/10.1038\/s41531-021-00242-2","journal-title":"npj Parkinsons Dis"},{"key":"13933_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-024-01873-1","author":"Z Wang","year":"2024","unstructured":"Wang Z, Gilliland T, Kim HJ et al (2024) A minimally invasive biomarker for sensitive and accurate diagnosis of Parkinson\u2019s disease. Acta Neuropathol Commun. https:\/\/doi.org\/10.1186\/s40478-024-01873-1","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"13933_CR48","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3233\/jpd-230390","volume":"14","author":"E Schaeffer","year":"2024","unstructured":"Schaeffer E, Kluge A, Schulte C et al (2024) Association of misfolded \u03b1-synuclein derived from neuronal exosomes in blood with Parkinson\u2019s disease diagnosis and duration. Journal of Parkinson\u2019s Disease 14(4):667\u2013679. https:\/\/doi.org\/10.3233\/jpd-230390","journal-title":"Journal of Parkinson\u2019s Disease"},{"key":"13933_CR49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.parkreldis.2022.10.007","volume":"104","author":"D Yoo","year":"2022","unstructured":"Yoo D, Bang J-I, Ahn C et al (2022) Diagnostic value of \u03b1-synuclein seeding amplification assays in \u03b1-synucleinopathies: a systematic review and meta-analysis. Parkinsonism Relat Disord 104:99\u2013109. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.10.007","journal-title":"Parkinsonism Relat Disord"},{"key":"13933_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00519-8","author":"A Kuzkina","year":"2023","unstructured":"Kuzkina A, R\u00f6\u00dfle J, Seger A et al (2023) Combining skin and olfactory \u03b1-synuclein seed amplification assays (SAA)\u2014towards biomarker-driven phenotyping in synucleinopathies. npj Parkinsons Dis. https:\/\/doi.org\/10.1038\/s41531-023-00519-8","journal-title":"npj Parkinsons Dis"},{"key":"13933_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107088","volume":"127","author":"M Luan","year":"2024","unstructured":"Luan M, Wei L, Sun Y et al (2024) Combining salivary \u03b1-synuclein seeding activity and miRNA-29a to distinguish Parkinson\u2019s disease and multiple system atrophy. Parkinsonism Relat Disord 127:107088. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107088","journal-title":"Parkinsonism Relat Disord"},{"key":"13933_CR52","doi-asserted-by":"publisher","DOI":"10.1101\/2025.10.22.25337489","author":"WM J\u00fcrgens-Wemheuer","year":"2025","unstructured":"J\u00fcrgens-Wemheuer WM, Martens D, Spiegel J et al (2025) Evaluation of submandibular gland biopsies with RT-QuIC in Parkinson\u2019s disease under investigation. medRxiv. https:\/\/doi.org\/10.1101\/2025.10.22.25337489","journal-title":"medRxiv"},{"key":"13933_CR53","doi-asserted-by":"publisher","DOI":"10.1101\/2024.03.29.24304902","author":"A Kluge","year":"2024","unstructured":"Kluge A, Kintrup C, Kulcsarova K et al (2024) Alpha-synuclein distribution and seeding activity in rectal biopsies in Parkinson\u2019s disease. MedRxiv. https:\/\/doi.org\/10.1101\/2024.03.29.24304902","journal-title":"MedRxiv"},{"key":"13933_CR54","doi-asserted-by":"publisher","DOI":"10.1212\/cpj.0000000000001116","author":"E Angelopoulou","year":"2021","unstructured":"Angelopoulou E, Bougea A, Papadopoulos A et al (2021) CSF and circulating NfL as biomarkers for the discrimination of Parkinson disease from atypical Parkinsonian syndromes. Neurol Clin Pract. https:\/\/doi.org\/10.1212\/cpj.0000000000001116","journal-title":"Neurol Clin Pract"},{"issue":"11","key":"13933_CR55","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","volume":"69","author":"S Hall","year":"2012","unstructured":"Hall S, \u00d6hrfelt A, Constantinescu R et al (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or Parkinsonian Disorders. Arch Neurol 69(11):1445. https:\/\/doi.org\/10.1001\/archneurol.2012.1654","journal-title":"Arch Neurol"},{"key":"13933_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-021-00232-4","author":"C Quadalti","year":"2021","unstructured":"Quadalti C, Calandra-Buonaura G, Baiardi S et al (2021) Neurofilament light chain and \u03b1-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes. npj Parkinsons Dis. https:\/\/doi.org\/10.1038\/s41531-021-00232-4","journal-title":"npj Parkinsons Dis"},{"key":"13933_CR57","doi-asserted-by":"publisher","first-page":"105226","DOI":"10.1016\/j.parkreldis.2022.11.018","volume":"106","author":"K Oliveira Hauer","year":"2023","unstructured":"Oliveira Hauer K, Pawlik D, Leuzy A et al (2023) Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy. Parkinsonism Relat Disord 106:105226. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.11.018","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"13933_CR58","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s10286-023-00974-6","volume":"33","author":"W Singer","year":"2023","unstructured":"Singer W, Schmeichel AM, Sletten DM et al (2023) Neurofilament light chain in spinal fluid and plasma in multiple system atrophy: a prospective, longitudinal biomarker study. Clin Auton Res 33(6):635\u2013645. https:\/\/doi.org\/10.1007\/s10286-023-00974-6","journal-title":"Clin Auton Res"},{"issue":"10","key":"13933_CR59","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson O, Janelidze S, Hall S et al (2017) Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88(10):930\u2013937","journal-title":"Neurology"},{"key":"13933_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-00951-y","author":"S Baiardi","year":"2025","unstructured":"Baiardi S, Rossi M, Giannini G et al (2025) Head-to-head comparison of four cerebrospinal fluid and three plasma neurofilament light chain assays in Parkinsonism. npj Parkinson\u2019s Dis. https:\/\/doi.org\/10.1038\/s41531-025-00951-y","journal-title":"npj Parkinson\u2019s Dis"},{"key":"13933_CR61","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000007179","author":"TM Marques","year":"2019","unstructured":"Marques TM, van Rumund A, Oeckl P et al (2019) Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology. https:\/\/doi.org\/10.1212\/wnl.0000000000007179","journal-title":"Neurology"},{"key":"13933_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-020-00385-5","author":"ASL Ng","year":"2020","unstructured":"Ng ASL, Tan YJ, Yong ACW et al (2020) Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson\u2019s disease. Mol Neurodegener. https:\/\/doi.org\/10.1186\/s13024-020-00385-5","journal-title":"Mol Neurodegener"},{"key":"13933_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-00990-x","author":"N Candelise","year":"2020","unstructured":"Candelise N, Baiardi S, Franceschini A, Rossi M, Parchi P (2020) Towards an improved early diagnosis of neurodegenerative diseases: the emerging role of in vitro conversion assays for protein amyloids. Acta Neuropathol Commun. https:\/\/doi.org\/10.1186\/s40478-020-00990-x","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"13933_CR64","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/brain\/awab431","volume":"145","author":"I Poggiolini","year":"2021","unstructured":"Poggiolini I, Gupta V, Lawton M et al (2021) Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain 145(2):584\u2013595. https:\/\/doi.org\/10.1093\/brain\/awab431","journal-title":"Brain"},{"key":"13933_CR65","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000210279","author":"DG Coughlin","year":"2025","unstructured":"Coughlin DG, Shifflett B, Farris CM et al (2025) \u03b1-Synuclein seed amplification assay amplification parameters and the risk of progression in prodromal Parkinson disease. Neurology. https:\/\/doi.org\/10.1212\/wnl.0000000000210279","journal-title":"Neurology"},{"key":"13933_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-021-01282-8","author":"MJ Russo","year":"2021","unstructured":"Russo MJ, Orru CD, Concha-Marambio L et al (2021) High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson\u2019s disease. Acta Neuropathol Commun. https:\/\/doi.org\/10.1186\/s40478-021-01282-8","journal-title":"Acta Neuropathol Commun"},{"issue":"12","key":"13933_CR67","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1002\/mds.30019","volume":"39","author":"DP Vaughan","year":"2024","unstructured":"Vaughan DP, Fumi R, Theilmann Jensen M et al (2024) Evaluation of cerebrospinal fluid \u03b1-synuclein seed amplification assay in progressive supranuclear palsy and corticobasal syndrome. Mov Disord 39(12):2285\u20132291. https:\/\/doi.org\/10.1002\/mds.30019","journal-title":"Mov Disord"},{"issue":"6","key":"13933_CR68","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209818","volume":"103","author":"C Anastassiadis","year":"2024","unstructured":"Anastassiadis C, Martinez-Valbuena I, Vasilevskaya A et al (2024) CSF \u03b1-synuclein seed amplification assay in patients with atypical Parkinsonian disorders. Neurology 103(6):e209818. https:\/\/doi.org\/10.1212\/WNL.0000000000209818","journal-title":"Neurology"},{"key":"13933_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105925","volume":"120","author":"I Martinez-Valbuena","year":"2025","unstructured":"Martinez-Valbuena I, Fullam S, O\u2019Dowd S, Tartaglia MC, Kovacs GG (2025) \u03b1-Synuclein seed amplification assay positivity beyond synucleinopathies. EBioMedicine 120:105925. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105925","journal-title":"EBioMedicine"},{"issue":"4","key":"13933_CR70","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1002\/alz.13658","volume":"20","author":"G Bellomo","year":"2024","unstructured":"Bellomo G, Toja A, Paolini Paoletti F et al (2024) Investigating alpha-synuclein co-pathology in Alzheimer\u2019s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay. Alzheimers Dement 20(4):2444\u20132452. https:\/\/doi.org\/10.1002\/alz.13658","journal-title":"Alzheimers Dement"},{"issue":"8","key":"13933_CR71","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.1002\/alz.13858","volume":"20","author":"D Tosun","year":"2024","unstructured":"Tosun D, Hausle Z, Iwaki H et al (2024) A cross-sectional study of \u03b1-synuclein seed amplification assay in Alzheimer\u2019s disease neuroimaging initiative: prevalence and associations with Alzheimer\u2019s disease biomarkers and cognitive function. Alzheimers Dement 20(8):5114\u20135131. https:\/\/doi.org\/10.1002\/alz.13858","journal-title":"Alzheimers Dement"},{"issue":"8","key":"13933_CR72","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.1002\/alz.14039","volume":"20","author":"S Baiardi","year":"2024","unstructured":"Baiardi S, Hansson O, Levin J, Parchi P (2024) In vivo detection of Alzheimer\u2019s and Lewy body disease concurrence: clinical implications and future perspectives. Alzheimers Dement 20(8):5757\u20135770. https:\/\/doi.org\/10.1002\/alz.14039","journal-title":"Alzheimers Dement"},{"issue":"6","key":"13933_CR73","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/mds.30184","volume":"40","author":"S Weber","year":"2025","unstructured":"Weber S, Farris CM, Ma Y et al (2025) Anosmia and upper limb rigidity-a potential phenotype of idiopathic normal pressure hydrocephalus with cerebrospinal fluid \u03b1-synuclein seeds. Mov Disord 40(6):1206\u20131213. https:\/\/doi.org\/10.1002\/mds.30184","journal-title":"Mov Disord"},{"key":"13933_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2025.107857","volume":"136","author":"JK Yu","year":"2025","unstructured":"Yu JK, Choi HJ, Kim D et al (2025) Prevalence and clinical impact of alpha-synuclein pathology in idiopathic normal pressure hydrocephalus: Insights from RT-QuIC assay. Parkinsonism Relat Disord 136:107857. https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107857","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"13933_CR75","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/ana.26505","volume":"92","author":"A Fasano","year":"2022","unstructured":"Fasano A, Martinez-Valbuena I, Azevedo P et al (2022) Alpha-synuclein RT-QuIC in idiopathic normal pressure hydrocephalus. Ann Neurol 92(6):985\u2013991. https:\/\/doi.org\/10.1002\/ana.26505","journal-title":"Ann Neurol"},{"issue":"10","key":"13933_CR76","doi-asserted-by":"publisher","first-page":"6991","DOI":"10.1007\/s00415-024-12647-z","volume":"271","author":"S Katzdobler","year":"2024","unstructured":"Katzdobler S, N\u00fcbling G, Klietz M et al (2024) GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA). J Neurol 271(10):6991\u20136999. https:\/\/doi.org\/10.1007\/s00415-024-12647-z","journal-title":"J Neurol"},{"key":"13933_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2020.05.033","author":"S Mangesius","year":"2020","unstructured":"Mangesius S, Mariotto S, Ferrari S et al (2020) Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. Parkinsonism Relat Disord. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.05.033","journal-title":"Parkinsonism Relat Disord"},{"key":"13933_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.909552","author":"P Zhang","year":"2022","unstructured":"Zhang P, Chen J, Cai T et al (2022) Quantitative susceptibility mapping and blood neurofilament light chain differentiate between parkinsonian disorders. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2022.909552","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"13933_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci15030241","volume":"15","author":"S Demiri","year":"2025","unstructured":"Demiri S, Veltsista D, Siokas V et al (2025) Neurofilament light chain in cerebrospinal fluid and blood in multiple system atrophy: a systematic review and meta-analysis. Brain Sci 15(3):241. https:\/\/doi.org\/10.3390\/brainsci15030241","journal-title":"Brain Sci"},{"issue":"1","key":"13933_CR80","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3233\/jpd-191766","volume":"10","author":"C-H Chen","year":"2019","unstructured":"Chen C-H, Lee B-C, Lin C-H (2019) Integrated Plasma and neuroimaging biomarkers associated with motor and cognition severity in Parkinson\u2019s disease. J Parkinsons Dis 10(1):77\u201388. https:\/\/doi.org\/10.3233\/jpd-191766","journal-title":"J Parkinsons Dis"},{"key":"13933_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.805953","author":"Q Li","year":"2022","unstructured":"Li Q, Li Z, Han X et al (2022) A panel of plasma biomarkers for differential diagnosis of Parkinsonian syndromes. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2022.805953","journal-title":"Front Neurosci"},{"key":"13933_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2026.1727812","author":"J Yao","year":"2026","unstructured":"Yao J, Ma J, Li P et al (2026) Combining plasma biomarkers, clinical parameters, and neuroimaging features for differential diagnosis of Parkinson\u2019s disease and atypical parkinsonian syndromes: a multidimensional modeling approach. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2026.1727812","journal-title":"Front Aging Neurosci"},{"issue":"11","key":"13933_CR83","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","volume":"86","author":"NK Magdalinou","year":"2015","unstructured":"Magdalinou NK, Paterson RW, Schott JM et al (2015) A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 86(11):1240\u20131247. https:\/\/doi.org\/10.1136\/jnnp-2014-309562","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13933_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00123","author":"C-H Lin","year":"2018","unstructured":"Lin C-H, Yang S-Y, Horng H-E et al (2018) Plasma biomarkers differentiate Parkinson\u2019s disease from atypical Parkinsonism syndromes. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2018.00123","journal-title":"Front Aging Neurosci"},{"key":"13933_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123617","volume":"476","author":"M Campagnolo","year":"2025","unstructured":"Campagnolo M, Fiorenzato E, Musso G et al (2025) The role of blood-based biomarkers in Parkinsonian disorders, Alzheimer\u2019s disease and frontotemporal dementia. J Neurol Sci 476:123617. https:\/\/doi.org\/10.1016\/j.jns.2025.123617","journal-title":"J Neurol Sci"},{"key":"13933_CR86","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-025-02853-y","author":"AM Bernhardt","year":"2025","unstructured":"Bernhardt AM, Longen S, Trossbach SV et al (2025) A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson\u2019s disease. Acta Neuropathol. https:\/\/doi.org\/10.1007\/s00401-025-02853-y","journal-title":"Acta Neuropathol"},{"key":"13933_CR87","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000201199","author":"N Majbour","year":"2022","unstructured":"Majbour N, Aasly J, Abdi I et al (2022) Disease-Associated \u03b1-synuclein aggregates as biomarkers of Parkinson disease clinical stage. Neurology. https:\/\/doi.org\/10.1212\/wnl.0000000000201199","journal-title":"Neurology"},{"issue":"6","key":"13933_CR88","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1093\/brain\/awae405","volume":"148","author":"A Mastrangelo","year":"2024","unstructured":"Mastrangelo A, Mammana A, Hall S et al (2024) Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum. Brain 148(6):2038\u20132048. https:\/\/doi.org\/10.1093\/brain\/awae405","journal-title":"Brain"},{"key":"13933_CR89","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000209656","author":"DG Coughlin","year":"2024","unstructured":"Coughlin DG, MacLeod KR, Middleton JS et al (2024) Association of CSF \u03b1-synuclein seeding amplification assay results with clinical features of possible and probable dementia with Lewy bodies. Neurology. https:\/\/doi.org\/10.1212\/wnl.0000000000209656","journal-title":"Neurology"},{"issue":"12","key":"13933_CR90","doi-asserted-by":"publisher","first-page":"5813","DOI":"10.1007\/s00415-023-11810-2","volume":"270","author":"JS Middleton","year":"2023","unstructured":"Middleton JS, Hovren HL, Kha N et al (2023) Seed amplification assay results illustrate discrepancy in Parkinson\u2019s disease clinical diagnostic accuracy and error rates. J Neurol 270(12):5813\u20135818. https:\/\/doi.org\/10.1007\/s00415-023-11810-2","journal-title":"J Neurol"},{"key":"13933_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2026.121101","volume":"590","author":"A L\u00f3pez-Bellido","year":"2026","unstructured":"L\u00f3pez-Bellido A, Marti-Navia A, Ch\u00e1fer-Peric\u00e1s C (2026) Systematic review of alpha-synuclein seed amplification assays for the detection of synucleinopathies. Clin Chim Acta 590:121101. https:\/\/doi.org\/10.1016\/j.cca.2026.121101","journal-title":"Clin Chim Acta"},{"issue":"9","key":"13933_CR92","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel C, van Wieringen WN, Zetterberg H et al (2019) Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol 76(9):1035\u20131048. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1534","journal-title":"JAMA Neurol"},{"issue":"1","key":"13933_CR93","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s40478-025-02151-4","volume":"13","author":"ZAM Al-Azzawi","year":"2025","unstructured":"Al-Azzawi ZAM, Silver NRG, Mehra S et al (2025) \u03b1-Synuclein purification significantly impacts seed amplification assay performance and consistency. Acta Neuropathol Commun 13(1):225. https:\/\/doi.org\/10.1186\/s40478-025-02151-4","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"13933_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0326568","volume":"20","author":"R Bsoul","year":"2025","unstructured":"Bsoul R, Simonsen AH, Frederiksen KS et al (2025) Seeding amplification assay with Universal Control Fluid: standardized detection of \u03b1-synucleinopathies. PLoS ONE 20(6):e0326568. https:\/\/doi.org\/10.1371\/journal.pone.0326568","journal-title":"PLoS ONE"},{"key":"13933_CR95","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.21.25328106","author":"C Janarthanam","year":"2025","unstructured":"Janarthanam C, Orr\u00fa CD, Kanthasamy AG et al (2025) Diagnostic accuracy in predicting the clinical diagnoses of Parkinson\u2019s Disease Parkinson\u2019s Disease with dementia and dementia with Lewy Bodies using skin biopsies analyzed with alpha-synuclein seed amplification assays. medRxiv. https:\/\/doi.org\/10.1101\/2025.05.21.25328106","journal-title":"medRxiv"},{"issue":"4","key":"13933_CR96","volume":"17","author":"OH McWilliam","year":"2025","unstructured":"McWilliam OH, Bsoul R, Lund EL et al (2025) \u03b1-Synuclein seed amplification assay in Lewy body dementia versus Alzheimer\u2019s disease. Alzheimer\u2019s Dement Diagn Assess Dis Monitoring 17(4):e70203","journal-title":"Alzheimer\u2019s Dement Diagn Assess Dis Monitoring"},{"key":"13933_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62458-7","author":"SE Mastenbroek","year":"2025","unstructured":"Mastenbroek SE, Collij LE, Vogel JW et al (2025) Two-step detection of Lewy body pathology via smell-function testing and CSF \u03b1-synuclein seed amplification. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-025-62458-7","journal-title":"Nat Commun"},{"key":"13933_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/alz70856_102894","volume":"21","author":"SE Mastenbroek","year":"2025","unstructured":"Mastenbroek SE, Collij LE, Vogel JW et al (2025) A conditional two-step approach for detecting Lewy Body pathology: smell function testing and \u03b1-synuclein seed amplification. Alzheimer\u2019s Dement 21:e102894","journal-title":"Alzheimer\u2019s Dement"},{"key":"13933_CR99","doi-asserted-by":"publisher","DOI":"10.1101\/2024.08.07.24311578","author":"CS Venuto","year":"2025","unstructured":"Venuto CS, Herbst K, Chahine LM, Kieburtz K (2025) Predicting cerebrospinal fluid alpha-synuclein seed amplification assay status from demographics and clinical data. medRxiv. https:\/\/doi.org\/10.1101\/2024.08.07.24311578","journal-title":"medRxiv"},{"key":"13933_CR100","doi-asserted-by":"publisher","DOI":"10.1002\/alz70856_106298","author":"D Fischer","year":"2025","unstructured":"Fischer D, Ellingson TN, Miller BL, Vandevrede L (2025) Alpha-synuclein seeding amplification assay use and potential impact in a behavioral neurology clinic. Alzheimer\u2019s Dement. https:\/\/doi.org\/10.1002\/alz70856_106298","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"13933_CR101","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1017\/neu.2023.25","volume":"36","author":"MJY Kang","year":"2023","unstructured":"Kang MJY, Eratne D, Dobson H et al (2023) Cerebrospinal fluid neurofilament light predicts longitudinal diagnostic change in patients with psychiatric and neurodegenerative disorders. Acta Neuropsychiatr 36(1):17\u201328. https:\/\/doi.org\/10.1017\/neu.2023.25","journal-title":"Acta Neuropsychiatr"},{"issue":"5","key":"13933_CR102","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/acn3.52034","volume":"11","author":"MJ Plastini","year":"2024","unstructured":"Plastini MJ, Abdelnour C, Young CB et al (2024) Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer\u2019s disease spectra. Ann Clin Transl Neurol 11(5):1197\u20131210. https:\/\/doi.org\/10.1002\/acn3.52034","journal-title":"Ann Clin Transl Neurol"},{"key":"13933_CR103","doi-asserted-by":"publisher","DOI":"10.1002\/mds.70086","author":"C Painous","year":"2026","unstructured":"Painous C, Fern\u00e1ndez M, C\u00e1mara A et al (2026) Barcelona progressive supranuclear palsy (PSP) registry: clinical, oculomotor, and cerebrospinal fluid markers; from suggestive to definite cases. Mov Disord. https:\/\/doi.org\/10.1002\/mds.70086","journal-title":"Mov Disord"},{"issue":"5","key":"13933_CR104","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3233\/jpd-230065","volume":"13","author":"L Oftedal","year":"2023","unstructured":"Oftedal L, Maple-Gr\u00f8dem J, Tysnes O-B, Alves G, Lange J (2023) Seed amplification assay as a diagnostic tool in newly-diagnosed Parkinson\u2019s disease. J Parkinson\u2019s Dis 13(5):841\u2013844. https:\/\/doi.org\/10.3233\/jpd-230065","journal-title":"J Parkinson\u2019s Dis"},{"issue":"9","key":"13933_CR105","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1007\/s00415-023-11741-y","volume":"270","author":"L Peng","year":"2023","unstructured":"Peng L, Wan L, Liu M et al (2023) Diagnostic and prognostic performance of plasma neurofilament light chain in multiple system atrophy: a cross-sectional and longitudinal study. J Neurol 270(9):4248\u20134261. https:\/\/doi.org\/10.1007\/s00415-023-11741-y","journal-title":"J Neurol"},{"issue":"1","key":"13933_CR106","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/ene.14032","volume":"27","author":"MG F\u00f8rland","year":"2019","unstructured":"F\u00f8rland MG, Tysnes O-B, Aarsland D et al (2019) The value of cerebrospinal fluid \u03b1-synuclein and the tau\/\u03b1-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology. Euro J Neurol 27(1):43\u201350. https:\/\/doi.org\/10.1111\/ene.14032","journal-title":"Euro J Neurol"},{"issue":"8","key":"13933_CR107","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","volume":"29","author":"C Quadalti","year":"2023","unstructured":"Quadalti C, Palmqvist S, Hall S et al (2023) Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat Med 29(8):1964\u20131970. https:\/\/doi.org\/10.1038\/s41591-023-02449-7","journal-title":"Nat Med"},{"issue":"5","key":"13933_CR108","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/ana.25447","volume":"85","author":"A van Rumund","year":"2019","unstructured":"van Rumund A, Green AJE, Fairfoul G et al (2019) \u03b1-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of Parkinsonism. Ann Neurol 85(5):777\u2013781. https:\/\/doi.org\/10.1002\/ana.25447","journal-title":"Ann Neurol"},{"issue":"7S_Part_7","key":"13933_CR109","doi-asserted-by":"publisher","first-page":"P375","DOI":"10.1016\/j.jalz.2018.06.255","volume":"14","author":"DR Galasko","year":"2018","unstructured":"Galasko DR, Groveman BR, Orru CD et al (2018) P1\u2013250: rapid and ultra-sensitive detection of \u03b1-synuclein seeds in brain and cerebrospinal fluid by \u03b1-SYN RT-QUIC: an aid to diagnosis for PD and DLB. Alzheimer\u2019s Dement 14(7S_Part_7):P375\u2013P375","journal-title":"Alzheimer\u2019s Dement"},{"key":"13933_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2025.120349","volume":"574","author":"N Upadhyay","year":"2025","unstructured":"Upadhyay N, Tripathi M, Chaddha RK et al (2025) Tailored pharmacotherapy monitoring in Parkinson\u2019s disease and schizophrenia using a rapid and sensitive \u03b1-synuclein assay. Clin Chim Acta 574:120349. https:\/\/doi.org\/10.1016\/j.cca.2025.120349","journal-title":"Clin Chim Acta"},{"key":"13933_CR111","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-63386\/v1","author":"N Ashton","year":"2020","unstructured":"Ashton N, Janelidze S, Khleifat AA et al (2020) Diagnostic value of plasma neurofilament light: a multicentre validation study. Res Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-63386\/v1","journal-title":"Res Sq"},{"issue":"6","key":"13933_CR112","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/jnc.15601","volume":"161","author":"J Ren","year":"2022","unstructured":"Ren J, Pan C, Wang Y et al (2022) Plasma \u03b1-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson\u2019s disease. J Neurochem 161(6):506\u2013515. https:\/\/doi.org\/10.1111\/jnc.15601","journal-title":"J Neurochem"},{"issue":"5","key":"13933_CR113","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.12793","volume":"9","author":"RZ Rousset","year":"2026","unstructured":"Rousset RZ, Honey MIJ, den Braber A et al (2026) Glial fibrillary acidic protein and neurofilament light reference intervals in healthy individuals. JAMA Netw Open 9(5):e2612793. https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.12793","journal-title":"JAMA Netw Open"},{"issue":"24","key":"13933_CR114","doi-asserted-by":"publisher","first-page":"25729","DOI":"10.18632\/aging.203790","volume":"13","author":"M Koini","year":"2021","unstructured":"Koini M, Pirpamer L, Hofer E et al (2021) Factors influencing serum neurofilament light chain levels in normal aging. Aging (Albany NY) 13(24):25729\u201325738. https:\/\/doi.org\/10.18632\/aging.203790","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"13933_CR115","doi-asserted-by":"publisher","first-page":"15863","DOI":"10.1038\/s41598-022-20398-y","volume":"12","author":"M Hermesdorf","year":"2022","unstructured":"Hermesdorf M, Leppert D, Maceski A et al (2022) Longitudinal analyses of serum neurofilament light and associations with obesity indices and bioelectrical impedance parameters. Sci Rep 12(1):15863. https:\/\/doi.org\/10.1038\/s41598-022-20398-y","journal-title":"Sci Rep"},{"issue":"1","key":"13933_CR116","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200045","volume":"10","author":"Y Yalachkov","year":"2023","unstructured":"Yalachkov Y, Sch\u00e4fer JH, Jakob J et al (2023) Effect of estimated blood volume and body mass index on GFAP and NfL levels in the serum and CSF of patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 10(1):e200045. https:\/\/doi.org\/10.1212\/NXI.0000000000200045","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13933_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.819010","volume":"16","author":"AA Polymeris","year":"2022","unstructured":"Polymeris AA, Helfenstein F, Benkert P et al (2022) Renal function and body mass index contribute to serum neurofilament light chain levels in elderly patients with atrial fibrillation. Front Neurosci 16:819010. https:\/\/doi.org\/10.3389\/fnins.2022.819010","journal-title":"Front Neurosci"},{"issue":"4","key":"13933_CR118","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ana.26446","volume":"92","author":"KC Fitzgerald","year":"2022","unstructured":"Fitzgerald KC, Sotirchos ES, Smith MD et al (2022) Contributors to serum NfL levels in people without neurologic disease. Ann Neurol 92(4):688\u2013698. https:\/\/doi.org\/10.1002\/ana.26446","journal-title":"Ann Neurol"},{"key":"13933_CR119","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvag053","author":"O Evliyaoglu","year":"2026","unstructured":"Evliyaoglu O, Findeisen P, Rausch H-W et al (2026) Age-dependent z scores and eGFR-adjusted reference ranges for neurofilament light: a practical approach for clinical laboratories. Clin Chem. https:\/\/doi.org\/10.1093\/clinchem\/hvag053","journal-title":"Clin Chem"},{"issue":"1","key":"13933_CR120","doi-asserted-by":"publisher","first-page":"20350","DOI":"10.1038\/s41598-020-76990-7","volume":"10","author":"S Akamine","year":"2020","unstructured":"Akamine S, Marutani N, Kanayama D et al (2020) Renal function is associated with blood neurofilament light chain level in older adults. Sci Rep 10(1):20350. https:\/\/doi.org\/10.1038\/s41598-020-76990-7","journal-title":"Sci Rep"},{"issue":"2","key":"13933_CR121","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1210\/clinem\/dgac580","volume":"108","author":"S Ciardullo","year":"2023","unstructured":"Ciardullo S, Muraca E, Bianconi E et al (2023) Diabetes mellitus is associated with higher serum neurofilament light chain levels in the general us population. J Clin Endocrinol Metab 108(2):361\u2013367. https:\/\/doi.org\/10.1210\/clinem\/dgac580","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"13933_CR122","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00125-022-05846-8","volume":"66","author":"H Maalmi","year":"2023","unstructured":"Maalmi H, Strom A, Petrera A et al (2023) Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy. Diabetologia 66(3):579\u2013589. https:\/\/doi.org\/10.1007\/s00125-022-05846-8","journal-title":"Diabetologia"},{"issue":"12","key":"13933_CR123","doi-asserted-by":"publisher","first-page":"e2248593","DOI":"10.1001\/jamanetworkopen.2022.48593","volume":"5","author":"J Fundaun","year":"2022","unstructured":"Fundaun J, Kolski M, Molina-\u00c1lvarez M, Baskozos G, Schmid AB (2022) Types and concentrations of blood-based biomarkers in adults with peripheral neuropathies: a systematic review and meta-analysis. JAMA Netw Open 5(12):e2248593. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.48593","journal-title":"JAMA Netw Open"},{"issue":"3","key":"13933_CR124","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/mus.28467","volume":"72","author":"AM Faust","year":"2025","unstructured":"Faust AM, DeMartini SJ, Dy CJ, Brogan DM (2025) Serum biomarkers for traumatic peripheral nerve injury: a systematic review. Muscle Nerve 72(3):383\u2013392. https:\/\/doi.org\/10.1002\/mus.28467","journal-title":"Muscle Nerve"},{"issue":"1","key":"13933_CR125","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.70038","volume":"36","author":"S Streit","year":"2026","unstructured":"Streit S, Meinhardt J, Gimber N et al (2026) Neurofilament light chain as a marker of peripheral nerve damage in vasculitic neuropathy? A cross-compartmental correlation analysis in patients undergoing nerve biopsy. Brain Pathol 36(1):e70038. https:\/\/doi.org\/10.1111\/bpa.70038","journal-title":"Brain Pathol"},{"issue":"5","key":"13933_CR126","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","volume":"20","author":"M Khalil","year":"2024","unstructured":"Khalil M, Teunissen CE, Lehmann S et al (2024) Neurofilaments as biomarkers in neurological disorders - towards clinical application. Nat Rev Neurol 20(5):269\u2013287. https:\/\/doi.org\/10.1038\/s41582-024-00955-x","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"13933_CR127","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/brain\/awac328","volume":"146","author":"S Abu-Rumeileh","year":"2023","unstructured":"Abu-Rumeileh S, Abdelhak A, Foschi M et al (2023) The multifaceted role of neurofilament light chain protein in non-primary neurological diseases. Brain 146(2):421\u2013437. https:\/\/doi.org\/10.1093\/brain\/awac328","journal-title":"Brain"},{"issue":"8","key":"13933_CR128","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"L Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P et al (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8):870\u2013881. https:\/\/doi.org\/10.1136\/jnnp-2018-320106","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13933_CR129","doi-asserted-by":"publisher","DOI":"10.1002\/alz.089116","volume":"20","author":"A Porter","year":"2024","unstructured":"Porter A, Lachner C, Tipton PW, Graff-Radford NR, Day GS (2024) Diagnostic Performance and clinical applications of a commercial alpha-synuclein seed amplification assay in a tertiary care memory clinic. Alzheimer\u2019s Dement 20:e089116","journal-title":"Alzheimer\u2019s Dement"},{"key":"13933_CR130","doi-asserted-by":"publisher","DOI":"10.1101\/2025.06.10.658994","author":"L Higginbotham","year":"2025","unstructured":"Higginbotham L, Shantaraman A, Guo Q et al (2025) Multiplex proteomics of lewy body dementia reveals cerebrospinal fluid biomarkers of disease pathology and progression. bioRxiv. https:\/\/doi.org\/10.1101\/2025.06.10.658994","journal-title":"bioRxiv"},{"key":"13933_CR131","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.02.24312694","author":"M Schuler","year":"2024","unstructured":"Schuler M, Gerwert G, Mann M et al (2024) Alpha-synuclein misfolding as a fluid biomarker for Parkinson\u2019s disease and synucleinopathies measured with the iRS platform. medRxiv. https:\/\/doi.org\/10.1101\/2024.09.02.24312694","journal-title":"medRxiv"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13933-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13933-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13933-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:21:52Z","timestamp":1783495312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13933-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":131,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["13933"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13933-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"397"}}